Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Non-Current Debt: 2019-2022

Historic Non-Current Debt for Pharming Group N.V (PHAR) over the last 2 years, with Sep 2022 value amounting to $143,000.

  • Pharming Group N.V's Non-Current Debt fell 62.95% to $143,000 in Q3 2022 from the same period last year, while for Sep 2022 it was $143,000, marking a year-over-year decrease of 62.95%. This contributed to the annual value of $165,000 for FY2021, which is 22.17% down from last year.
  • As of Q3 2022, Pharming Group N.V's Non-Current Debt stood at $143,000, which was down 5.92% from $152,000 recorded in Q2 2022.
  • Over the past 5 years, Pharming Group N.V's Non-Current Debt peaked at $19.4 million during Q4 2019, and registered a low of $143,000 during Q3 2022.
  • Its 3-year average for Non-Current Debt is $200,401, with a median of $177,000 in 2021.
  • Data for Pharming Group N.V's Non-Current Debt shows a maximum YoY tumbled of 98.91% (in 2020) over the last 5 years.
  • Pharming Group N.V's Non-Current Debt (Quarterly) stood at $19.4 million in 2019, then slumped by 98.91% to $212,000 in 2020, then fell by 22.17% to $165,000 in 2021, then slumped by 62.95% to $143,000 in 2022.
  • Its Non-Current Debt stands at $143,000 for Q3 2022, versus $152,000 for Q2 2022 and $162,000 for Q1 2022.